Skip to search formSkip to main contentSkip to account menu

VE-822

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

VX-970

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
Only few drugs have shown activity in patients with advanced soft-tissue and the median overall survival is only 18 months… 
2018
2018
RDNA-12. ATR INHIBITOR VE-822 IS A NOVEL RADIO- SENSITIZER FOR GLIOMA
2018
2018
Abstract LB-086: ATR inhibition broadly sensitizes TP53-deficient soft-tissue sarcomas to chemotherapy independent of alternative lengthening telomere (ALT) status: Moving forward to personalized…
Background: Despite optimal local treatment, 40 to 50% of patients with soft-tissue sarcomas (STS) will develop metastatic… 
2017
2017
Abstract 1187: Synthetic lethality screening reveals ATR as responsible for oxaliplatin resistance in colorectal cancer cells
Despite the recent advances achieved in the treatment of colon cancer, tumor resistance is a frequent cause of chemotherapy… 
Review
2017
Review
2017
ATR is a Novel Therapeutic Target for Medulloblastoma Identified by its Role in Cerebellar Development
Patrick Y. Lang: ATR is a novel therapeutic target for medulloblastoma identified by its role in cerebellar development (Under… 
2015
2015
Using gamma-H2AX and H2AX quantitative ELISA for monitoring DNA damage induced by chemotherapeutic agents and irradiation exposure.
2559 Background: Gamma-H2AX (γH2AX) is a biomarker for DNA double-strand breaks and programmed cell death, but variable relative… 
2013
2013
Abstract LB-299: Comprehensive preclinical evaluation of VE-822, the first ATR-targeted drug candidate: a novel approach to transforming the efficacy of DNA damaging agents.
DNA damaging agents have been the cornerstone of cancer therapy for decades yet they provide only modest benefit for most… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)